These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38669725)

  • 1. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
    Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
    World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
    Huang H; Li L; Tong L; Luo H; Luo H; Zhang Q
    PLoS One; 2024; 19(9):e0310808. PubMed ID: 39312569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    Han Y; Xiao X; Qin T; Yao S; Liu X; Feng Y; Li Z; Li Y; Xia S
    Cancer Immunol Immunother; 2024 Oct; 73(12):262. PubMed ID: 39382658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
    Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
    Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
    Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
    Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 16. Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
    Gallina FT; Balzano V; Porciello N; Tajè R; Forcella D; Melis E; Letizia Cecere F; Fusco F; Buglioni S; Visca P; Nisticò P; Cappuzzo F; Spicer J
    Lung Cancer; 2024 Aug; 194():107900. PubMed ID: 39079181
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
    Hines JB; Cameron RB; Esposito A; Kim L; Porcu L; Nuccio A; Viscardi G; Ferrara R; Veronesi G; Forde PM; Taube J; Vokes E; Bestvina CM; Dolezal JM; Sacco M; Monteforte M; Cascone T; Garassino MC; Torri V
    J Thorac Oncol; 2024 Jul; 19(7):1108-1116. PubMed ID: 38461929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
    Marinelli D; Gallina FT; Pannunzio S; Di Civita MA; Torchia A; Giusti R; Gelibter AJ; Roberto M; Verrico M; Melis E; Tajè R; Cecere FL; Landi L; Nisticò P; Porciello N; Occhipinti M; Brambilla M; Forde PM; Liu SV; Botticelli A; Novello S; Ciliberto G; Cortesi E; Facciolo F; Cappuzzo F; Santini D
    Crit Rev Oncol Hematol; 2023 Dec; 192():104190. PubMed ID: 37871779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
    Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
    Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.